Citation Impact
Citing Papers
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies
2005
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
2005
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Osteoporosis
2019 Standout
Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
2013
Osteonecrosis of the jaw – Prevention and treatment strategies for oral health professionals
2013
Breast cancer
2016 Standout
Thyroid cancer
2016 Standout
Cancer to bone: a fatal attraction
2011 Standout
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
2014
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer
2012
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Unravelling the complexity of metastasis — molecular understanding and targeted therapies
2011
Metastatic Cancer Identified in Osteonecrosis Specimens of the Jaws in Patients Receiving Intravenous Bisphosphonate Medications
2013
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer
2011
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Osteoporosis: now and the future
2011 Standout
The molecular biology of head and neck cancer
2010 Standout
Bone cancer pain: Causes, consequences, and therapeutic opportunities
2013
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
2014
Breast Cancer Metastasis
2013
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
2011
Acute kidney injury
2019 Standout
Epidemiology and pathogenesis of osteonecrosis of the jaw
2011
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
2011
Capecitabine: A review
2005
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
2011
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Emerging Biological Principles of Metastasis
2017 Standout
The Role of Microbial Biofilms in Osteonecrosis of the Jaw Associated with Bisphosphonate Therapy
2010
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials
2013
Targeting metastasis
2016
Novel targets in gastric and esophageal cancer
2006
Colorectal cancer
2005
Cetuximab Therapy and Symptomatic Hypomagnesemia
2005
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis
2011
Future directions of bone-targeted therapy for metastatic breast cancer
2010
Integration of EGFR inhibitors with radiochemotherapy
2006
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
2007
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
2013 Standout
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Transient Receptor Potential Cation Channels in Disease
2007 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Skeletal and extraskeletal actions of denosumab
2012
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
2012
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
2007
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity
2014
Novel approaches to target the microenvironment of bone metastasis
2021
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
2012
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis
2012
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
2013
Magnesium in Man: Implications for Health and Disease
2014 Standout
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
2017 Standout
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
2005
Pain regulation by non-neuronal cells and inflammation
2016 StandoutScience
Periapical Disease and Bisphosphonates Induce Osteonecrosis of the Jaws in Mice
2013
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
2010
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Cancer Genome Landscapes
2013 StandoutScience
Nephrotoxicity of anticancer treatment
2016
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma
2005
Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization.
2007
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
2005
Works of Ada Braun being referenced
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Hypocalcaemia in patients with metastatic bone disease treated with denosumab
2015
New systemic frontline treatment for metastatic colorectal carcinoma
2004
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
2012
Pain outcomes in patients with advanced breast cancer and bone metastases
2012
The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
2012
Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
2012
2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study
2009
Denosumab for Treatment of Hypercalcemia of Malignancy
2014
A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases.
2009
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
2003